Scholarlink

<p>Arrhythmia is a type of cardiovascular disorder that can be fatal. Several methods for treating cardiac arrhythmia have been developed, the most significant of which are implantable cardiac defibrillator (ICD) placement and pharmaceutical therapy. The present study aimed to analyze the cost-effectiveness of an ICD strategy compared to the pharmaceutical therapy in patients with arrhythmia in Iran.This is an economic evaluation study that was carried out using the Markov model for lifetime time horizon. The study population includes all patients with cardiac arrhythmia hospitalized in Shafa hospital in Kerman, eastern-south of Iran, between 2017 and 2019. The study sample includes 101 patients who were treated using the ICD method and 101 randomly selected patients who were received pharmaceutical treatment. This study is conducted from the perspective of the health system, and only direct costs (medical and non-medical) are derived. The study’s outcome was defined as the quality-adjusted life-year (QALY). The data was analyzed using TreeAge software version 2020, and the incremental cost-effectiveness ratio (ICER) was compared to a willingness-to-pay (WTP) threshold of three times GDP per capita in 2021 ($13,002). Deterministic and probabilistic sensitivity analyses were performed to examine the effect of uncertain model parameters on cost effectiveness anlysis. The results revealed that the lifetime costs of ICD and pharmaceutical therapy strategies in treating cardiac arrhythmia were $41,135 and $8,592, respectively, with outcomes equal to 12.63 and 11.29 QALYs. The ICER of the ICD strategy compared to the pharmaceutical therapy was $24,286 per QALY, and it was not cost-effective. The probabilistic sensitivity analysis demonstrated that at a WTP of three times the GDP per capita, the ICD approach had a 40% cost-effectiveness probability. According to the findings of this study, the ICD strategy, when compared to pharmaceutical therapy, is not cost-effective for the treatment of patients with cardiac arrhythmia in Iran. Resource allocation and cost-cutting measures must be implemented as needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-effectiveness analysis of an implantable cardiac defibrillator compared with pharmaceutical therapy in patients hospitalized with arrhythmia in Iran

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月15日

查看全文
  • Tayyebeh Nowruzi,
  • Reza Goudarzi,
  • Maryam Aliramezany,
  • Mohammadreza Harandi Moghadam,
  • Gholamreza Bazmandegan,
  • Saman Najafi

摘要

Arrhythmia is a type of cardiovascular disorder that can be fatal. Several methods for treating cardiac arrhythmia have been developed, the most significant of which are implantable cardiac defibrillator (ICD) placement and pharmaceutical therapy. The present study aimed to analyze the cost-effectiveness of an ICD strategy compared to the pharmaceutical therapy in patients with arrhythmia in Iran.This is an economic evaluation study that was carried out using the Markov model for lifetime time horizon. The study population includes all patients with cardiac arrhythmia hospitalized in Shafa hospital in Kerman, eastern-south of Iran, between 2017 and 2019. The study sample includes 101 patients who were treated using the ICD method and 101 randomly selected patients who were received pharmaceutical treatment. This study is conducted from the perspective of the health system, and only direct costs (medical and non-medical) are derived. The study’s outcome was defined as the quality-adjusted life-year (QALY). The data was analyzed using TreeAge software version 2020, and the incremental cost-effectiveness ratio (ICER) was compared to a willingness-to-pay (WTP) threshold of three times GDP per capita in 2021 ($13,002). Deterministic and probabilistic sensitivity analyses were performed to examine the effect of uncertain model parameters on cost effectiveness anlysis. The results revealed that the lifetime costs of ICD and pharmaceutical therapy strategies in treating cardiac arrhythmia were $41,135 and $8,592, respectively, with outcomes equal to 12.63 and 11.29 QALYs. The ICER of the ICD strategy compared to the pharmaceutical therapy was $24,286 per QALY, and it was not cost-effective. The probabilistic sensitivity analysis demonstrated that at a WTP of three times the GDP per capita, the ICD approach had a 40% cost-effectiveness probability. According to the findings of this study, the ICD strategy, when compared to pharmaceutical therapy, is not cost-effective for the treatment of patients with cardiac arrhythmia in Iran. Resource allocation and cost-cutting measures must be implemented as needed.